Dr Naomi Fersht

Dr Naomi FershtTel: 020 3447 9287
Fax: 020 3447 9055
Email: brainoncologypa@uclh.nhs.uk

Location:
University College Hospital

Specialities:
Radiotherapy, Neuro-oncology (brain tumour unit), Neurology and neurosurgery

Professional background

Dr Naomi Fersht is a consultant clinical oncologist at University College Hospital and the National Hospital for Neurology and Neurosurgery. She specialises exclusively in the management of primary and secondary brain and spinal tumours. This involves the use of both conventional and innovative radiotherapy techniques and chemotherapy. 

Her special interests are: brain oligometastases; meningiomas; pituitary tumours; the management of teenagers and young adults with brain tumours (age 16-24); and advanced radiotherapy techniques including radiosurgery.

She qualified from the University of Cambridge and her specialist training was at the Royal Marsden and University College Hospitals. Naomi's doctoral thesis, supervised by Nobel Laureate Sir Paul Nurse, was in cell cycle checkpoints.

Research interests

Naomi's doctoral thesis, supervised by Nobel Laureate Sir Paul Nurse, was in cell cycle checkpoints.  She has been involved in evaluating novel molecular radiotherapy techniques for children with cancer and is now extending the use of these treatments to adults with selected types of brain tumour.

Publications

  • Craniospinal irradiation with concomitant and adjuvant temozolomide-a feasibility assessment of toxicity in patients with glioblastoma with a PNET component.
    O'Leary B, Mandeville HC, Fersht N, Solda F, Mycroft J, Zacharoulis S, Vaidya S, Saran F
    J Neurooncol. 2016 Apr;127(2):295-302
  • Evaluation of treatment response using integrated 18F-labeled choline positron emission tomography/magnetic resonance imaging in adolescents with intracranial non-germinomatous germ cell tumours.
    Tsouana E, Stoneham S, Fersht N, Kitchen N, Gaze M, Bomanji J, Fraioli F, Hargrave D, Shankar A.
    Pediatr Blood Cancer. 2015 Apr 8. doi: 10.1002/pbc.25538. [Epub ahead of print
  • Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort.
    Dénes J, Swords F, Rattenberry E, Stals K, Owens M, Cranston T, Xekouki P, Moran L, Kumar A, Wassif C, Fersht N, Baldeweg SE, Morris D, Lightman S, Agha A, Rees A, Grieve J, Powell M, Boguszewski CL, Dutta P, Thakker RV, Srirangalingam U, Thompson CJ, Druce M, Higham C, Davis J, Eeles R, Stevenson M, O'Sullivan B, Taniere P, Skordilis K, Gabrovska P, Barlier A, Webb SM, Aulinas A, Drake WM, Bevan JS, Preda C, Dalantaeva N, Ribeiro-Oliveira A Jr, Garcia IT, Yordanova G, Iotova V, Evanson J, Grossman AB, Trouillas J, Ellard S, Stratakis CA, Maher ER, Roncaroli F, Korbonits M.(2015)
    J Clin Endocrinol Metab. 2015 Mar;100(3):E531-41. doi: 10.1210/jc.2014-3399. Epub 2014 Dec 12
  • Radiation exposure to comforters and carers during paediatric molecular radiotherapy
    Gains JE, Walker C, Sullivan TM, Waddington WA, Fersht NL, Sullivan KP, Armstrong E, D'Souza DP, Aldridge MD, Bomanji JB, Gaze MN. (2014)
    Pediatr Blood Cancer. 2014 Oct 4. doi: 10.1002/pbc.25250.
  • Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/ carcinoma: variable clinical response in preliminary evaluation
    Maclean, M. Aldrich, J. Bomanji, S. Short , N. Fersht (2014)
    Pituitary. 2014 Dec;17(6):530-8
  • Controversies in Radiotherapy for Meningioma.
    Maclean, N. Fersht, S. Short. (2014)
    Clin Oncol (R Coll Radiol). 2014 Jan;26(1):51-64
  • Multi-disciplinary management for patients with oligometastases to the brain: Results of a 5 year cohort study
    Jillian Maclean, Naomi Fersht, Mausam Singhera, Paul Mulholland, Orla McKee, Neil Kitchen and Susan Short (2013)
    Radiation Oncology 06/2013;8(1):156
  • Sequential Transformation of Mesenchymal Stem Cells is Associated with increased radiosensitivity and reduced DNA repair capacity
    Worku M, Fersht N, Martindale C, Funes JM, Short SC (2013)
    Radiat Res. 2013 Jun;179(6):698-706.
  • Meningioma Causing Visual Impairment: Outcomes and Toxicity After Intensity Modulated Radiotherapy
    Jillian Maclean, Naomi Fersht, Fion Bremner, Chris Stacey, Suganya Sivabalasingham and Susan Short (2012)
    Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):e179-86
  • Radiotherapy for craniopharyngiomas
    Ajay Agarwal, Naomi Fersht and Michael Brada (2012)
    Pituitary. 2013 Mar;16(1):26-33
  • Arc delivered Intensity Modulated Radiotherapy achieves highly conformal radiotherapy for brain tumors with minimal hair loss
    Jillian Maclean, Christopher Stacey, Naomi Fersht, Ivan Rosenberg, Derek D’Souza, Nazima Haji, Julia Solano, Susan Short (2011)
    European Journal of Clinical and Medical Oncology 3:(4)
  • Preliminary Results from a Phase I/II Study of Intensity Modulated Radiotherapy in the Treatment of Meningiomas.
    Sivabalasingham S, Fersht N, D'Souza D, Rosenberg I, Stacey C, Davies P, Guerro-Urbano T, Short S (2011).
    CLIN ONCOL-UK, 23(3), S53 - S53
  • 177 Lutetium DOTATATE therapy for childhood neuroblastoma
    Jennifer E. Gains, Jamshed B. Bomanji, Naomi L. Fersht, Kevin P. Sullivan, Matthew Aldridge and Mark N. Gaze (2011)
    J Nucl Med 52(7):1041-7. Epub 2011 Jun 16.
  • Current experience with MIBG in combination with chemotherapy and radiosensitisers
    MN Gaze and NL Fersht (2008)
    Nuclear medicine and biology 35: S21-S26
  • Cdc18/CDC6 activates the Rad3-dependent checkpoint in the fission yeast
    N Fersht, D Hermand, J Hayles and P Nurse (2007)
    Nucleic Acids Research 35(16):5323-37. Epub 2007 Aug 8.
  • The role of radiotherapy in the management of patients with elevated calcitonin following initial surgery for medullary thyroid cancer
    Fersht N, Vini L, A'Hern R, Harmer C (2001)
    Thyroid 11(12):1161-8.
  • Axonal growth on astrocytes is not inhibited by oligodendrocytes
    Fawcett JW, Fersht N, Housden L, Schachner M, Pesheva P. (1992)
    J. Cell Science 103: 571-579.

GMC/GDC number: 4067553